市場調查報告書
商品編碼
1403393
結構生物學和分子建模技術市場預測至 2030 年:按產品、工具、技術、應用和地區進行的全球分析Structural Biology & Molecular Modeling Market Forecasts to 2030 - Global Analysis By Product, Tools (Software as a Service & Standalone Modeling, Visualization & Analysis, Databases and Other Tools), Technology, Application and By Geography |
根據Stratistics MRC預測,2023年全球結構生物學和分子建模技術市場規模將達到49.1億美元,預測期內複合年成長率為18.2%,預計到2030年將達到158.5億美元。
結構生物學和分子建模技術是兩個密切相關的領域,在分子層面上理解生物大分子的結構和功能方面發揮著重要作用。結構生物學和分子建模技術是多功能工具,可用於廣泛的應用,從基礎研究到醫學、農業和工業的實際應用。在分子層面上理解生物過程有助於許多科學和技術領域的進步。
根據 2021 年 9 月發表在 MDPI日誌上的一篇研究論文,周邊動脈疾病(PAD) 的盛行率估計在 3% 至 12% 之間,影響美國和歐洲約 2700 萬人。
慢性疾病通常涉及複雜的分子途徑。結構生物學透過提供詳細資訊來幫助識別和檢驗潛在的藥物研發標靶。結構生物學和分子建模技術有助於潛在藥物研發標靶的識別和特異性治療藥物的設計。癌症和神經退化性疾病等慢性病的增加加速了對標靶治療和個體化治療的需求。
儘管取得了進步,我們對複雜生物系統的理解仍在不斷發展中。對目標蛋白3D結構的有限了解阻礙了有效候選藥物的識別和設計。結果,藥物開發可能變得更慢、效率更低。此外,蛋白質-配體相互作用的預測準確性差和生物系統的複雜性等因素也阻礙了市場的成長。
人工智慧(AI)和機器學習(ML)在結構生物學和分子建模技術過程中的整合提高了資料分析的速度和準確性。人工智慧演算法可以分析生物資料來識別潛在的藥物研發標靶,為開發更有效率的藥物研發管道、提高治療效果並最大限度地減少副作用提供機會。我們提供此次整合將進一步提高該領域藥物研發發現和開發的效率、準確性和整體成功率。
結構生物學和分子建模技術通常需要昂貴的設備、軟體和熟練人員。它在很大程度上依賴尖端技術和專業設備。建立和維護最先進的實驗室和專業設施也需要大量的資本投資。此外,與分析實驗資料相關的成本,例如軟體許可證和解釋技術人員,也會增加整體初期成本並阻礙市場需求。
生命科學領域的許多研究工作都針對與新冠病毒相關的研究,包括疫苗開發、藥物再利用以及病毒結構和功能的闡明。這種資源的重新分配也影響了與新冠病毒無關的研究領域,例如結構生物學和分子建模。疫情期間的經濟不確定性和優先事項的轉變給研究計劃的資金籌措帶來了挑戰。此外,尋找新冠病毒治療方法的迫切需求增加了人們對抗病毒藥物發現的興趣和投資,間接使結構生物學和分子建模領域受益。
電子顯微鏡領域預計將出現良好的成長。電子顯微鏡技術提供高解析度,使研究人員能夠在分子甚至原子層面上可視化結構。電子顯微鏡是結構生物學和分子建模的強大工具,可提供對於理解生物過程和疾病機制至關重要的詳細結構資訊,並促進藥物研發工作。電磁技術的不斷進步正在增加其在該領域的重要性。
預計藥物研發領域在預測期內將出現最高的複合年成長率。結構生物學和分子建模技術透過提供對疾病分子機制的寶貴見解並促進新療法的設計,在藥物研發中發揮重要作用。這些技術可以幫助簡化藥物研發流程,使其更有效率且更具成本效益。
由於投資的增加和研發的進步,預計亞太地區在預測期內將佔據最大的市場佔有率。亞太地區的製藥和生物技術產業可能會對結構生物學和分子建模工具的需求做出重大貢獻。此外,政府對科學研究和生物技術的措施和資助也可以對市場產生積極影響。
由於不斷的進步、協作研究和夥伴關係,預計歐洲在預測期內將表現出最高的複合年成長率。政府資助、私人投資和津貼在促進該地區結構生物學和分子建模技術研究方面發揮著重要作用。歐洲市場的主要企業包括 Dassault Systemes、Agile Molecule 和 Acellera Limited。此外,資金籌措可用性和對個人化醫療日益成長的興趣可能會影響歐洲市場的成長。
According to Stratistics MRC, the Global Structural Biology & Molecular Modeling Market is accounted for $4.91 billion in 2023 and is expected to reach $15.85 billion by 2030 growing at a CAGR of 18.2% during the forecast period. Structural Biology and Molecular Modeling are two closely related fields that play a crucial role in understanding the structure and function of biological macromolecules at the molecular level. They are versatile tools with applications ranging from basic research to practical applications in medicine, agriculture, and industry. They provide a molecular-level understanding of biological processes, facilitating advancements in various scientific and technological fields.
According to the MDPI Journal research article published in September 2021, the prevalence of Peripheral Arterial Disease (PAD) is estimated to be 3-12%, affecting nearly 27 million people in America and Europe.
Chronic diseases often involve complex molecular pathways. Structural biology helps identify and validate potential drug targets by providing detailed information. Structural biology and molecular modeling contribute to the identification of potential drug targets and the design of specific therapeutics. The increasing prevalence of chronic diseases, such as cancer and neurodegenerative disorders, has fuelled the demand for targeted and personalized therapies.
Despite advancements, understanding of complex biological systems is still evolving. A limited understanding of the three-dimensional structures of target proteins can impede the identification and design of effective drug candidates. This can result in a slower and less efficient drug development process. Additionally, factors such as inaccuracy in predicting protein-ligand interactions and complexities of biological systems hampers the market growth.
The integration of artificial intelligence (AI) and machine learning (ML) in structural biology and molecular modeling processes enhances the speed and accuracy of data analysis. AI algorithms can analyze biological data to identify potential drug targets. It presents opportunities for the development of more efficient drug discovery pipelines, improving treatment efficacy and minimizing side effects. This integration further enhances the efficiency, accuracy, and overall success rate of drug discovery and development efforts in this field.
Structural biology and molecular modeling techniques often involve expensive equipment, software, and skilled personnel. They heavily rely on cutting-edge technologies and specialized equipment. Also, establishing & maintaining state-of-the-art laboratories and specialized facilities requires significant capital investment. Additionally, the costs associated with analyzing experimental data, including software licenses and skilled personnel for interpretation contribute to the overall initial expenses thereby hampering the market demand.
Many research efforts in the life sciences were redirected toward covid related studies, including vaccine development, drug repurposing, and understanding the virus's structure and function. This redirection of resources has impacted non-covid-related research areas, including structural biology and molecular modeling. Economic uncertainties and shifting priorities during the pandemic have led to funding challenges for research projects. Further, the urgency of finding treatments for covid has spurred increased interest and investment in antiviral drug discovery, which indirectly benefitted the structural biology and molecular modeling sector.
The electron microscopy segment is estimated to have a lucrative growth. Electron microscopy technique offers high resolution and allows researchers to visualize structures at the molecular and even atomic levels. It is a powerful tool in structural biology and molecular modeling, providing detailed structural information that is crucial for understanding biological processes, disease mechanisms, and facilitating drug discovery efforts. The continuous advancements in EM technology further contribute to its significance in the field.
The drug discovery segment is anticipated to witness the highest CAGR growth during the forecast period. Structural biology and molecular modeling play crucial roles in drug discovery by providing valuable insights into the molecular mechanisms of diseases and facilitating the design of novel therapeutic agents. These techniques help streamline the drug discovery pipeline, making it more efficient and cost-effective.
Asia Pacific is projected to hold the largest market share during the forecast period owing to the increasing investments and advances in research and development. The pharmaceutical and biotechnology industries in the Asia Pacific region are likely to contribute significantly to the demand for structural biology and molecular modeling tools. Further, government initiatives and funding for scientific research and biotechnology can positively influence the market.
Europe is projected to have the highest CAGR over the forecast period, owing to the continuous advancements, collaborations and partnerships. Government funding, private investments and grants play a significant role in advancing research in structural biology and molecular modeling in the region. Some prominent players in the European market include Dassault Systemes, Agile Molecule and Acellera Limited. Further, funding availability and growing emphasis on personalized medicine can impact the growth of the market in europe.
Some of the key players profiled in the Structural Biology & Molecular Modeling Market include Acellera Limited, Thermo Fisher Scientific Inc, Illumina Inc., Horiba, Chemical Computing Group ULC, Bruker Daltonics, Agilent Technologies Inc., Charles River Laboratories, Dassault Systemes, Biomax Informatics AG, Agile Molecule and Bioinformatic LLC.
In November 2023, The Accelra Company released a new version of ACEMD, Accela's molecular dynamics simulation software. ACEMD is a highly optimized molecular dynamics (MD) engine that runs on NVIDIA GPUs. It's free for non-profit research, but commercial licenses are available for other uses.
In September 2023, Thermo Scientific launched the new Hydra Bio Plasma-Focused Ion Beam (Plasma-FIB) for cell biologists seeking simplified workflows while undertaking volume electron microscopy for cryo or resin-embedded samples. The Hydra Bio Plasma-FIB is a versatile, multi-application instrument that supports volume electron microscopy and sample preparation for the cryo-electron tomography workflow.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.